Enzon Pharmaceuticals, Inc. (ENZN)
| Market Cap | 41.23M |
| Revenue (ttm) | 431,000 |
| Net Income (ttm) | -2.02M |
| Shares Out | 74.22M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $0.12 |
| Dividend Yield | 21.60% |
| Trading Day | May 13 |
| Last Price | $0.5555 |
| Previous Close | $0.5800 |
| Change ($) | -0.0245 |
| Change (%) | -4.22% |
| Day's Open | 0.5600 |
| Day's Range | 0.4775 - 0.5880 |
| Day's Volume | 218,572 |
| 52-Week Range | 0.0800 - 0.8500 |
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Compa...
Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously...
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”)...
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights off...
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits pre...
ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.
Trading for less than its liquid book value.
About ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.
| Industry Biotechnology | IPO Date Feb 15, 1984 |
| CEO Andrew Rackear | Country United States |
| Stock Exchange OTCMKTS | Ticker Symbol ENZN |
Financial Performance
In 2020, ENZN's revenue was $52,000, a decrease of -74.88% compared to the previous year's $207,000. Losses were -$1.31 million, 33.9% more than in 2019.